Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.33 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25755078 | 0.92 | PADI4 (0.33) | PADI4CYP19A1DPP4 | |
| SCHEMBL25755068 | 0.90 | PADI4 (0.34) | SLC6A2SLC6A4SLC6A3HTR4PADI4 | |
| SCHEMBL25755064 | 0.89 | DPP4 (0.32) | SLC6A2SLC6A4SLC6A3HTR4PADI4 | |
| SCHEMBL25755066 | 0.89 | PADI4 (0.33) | SLC6A2SLC6A4SLC6A3HTR4PADI4 | |
| SCHEMBL25755067 | 0.89 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3HTR4PADI4 | |
| SCHEMBL25755081 | 0.88 | PADI4 (0.35) | SLC6A2SLC6A4SLC6A3HTR4PADI4 | |
| SCHEMBL25755107 | 0.87 | CYP19A1 (0.34) | CYP19A1 | |
| SCHEMBL25755063 | 0.87 | PADI4 (0.33) | SLC6A2SLC6A4SLC6A3HTR4PADI4 | |
| SCHEMBL25755319 | 0.85 | THRB (0.36) | — | |
| SCHEMBL25754811 | 0.83 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3HTR4PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | SLC6A2 4723/4885SLC6A4 4774/4885SLC6A3 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.